文献速递白血病MDS 与骨髓增殖性肿瘤

Tagraxofusp联合阿扎胞苷±维奈克拉治疗急性髓系白血病的1b期试验

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

这项1b期研究纳入56例CD123阳性急性髓系白血病或高危骨髓增生异常综合征成人患者,先评估Tagraxofusp联合阿扎胞苷,后评估三药联合维奈克拉。Tagraxofusp推荐2期剂量为12 μg/kg/天连用3天,联合7天阿扎胞苷±21天维奈克拉。在26例初治欧洲白血病网不良风险急性髓系白血病扩展队列中,三药联合诱导缓解率69%,中位总生存14个月。

要点

  • Tagraxofusp联合阿扎胞苷±维奈克拉在CD123阳性急性髓系白血病中显示可控的安全性。
  • 推荐2期剂量为Tagraxofusp 12 μg/kg/天连用3天,联合7天阿扎胞苷±21天维奈克拉。
  • 三药联合在初治不良风险急性髓系白血病中诱导缓解率69%,支持进一步临床开发。

核心结论

  • Tagraxofusp联合阿扎胞苷和维奈克拉在高危急性髓系白血病(包括TP53突变疾病)中显示出令人鼓舞的安全性和活性,支持Tagraxofusp联合方案的进一步临床开发。

研究设计与样本

  • 1b期研究纳入56例CD123阳性急性髓系白血病或高危骨髓增生异常综合征成人患者,先评估Tagraxofusp联合阿扎胞苷,后评估Tagraxofusp、阿扎胞苷和维奈克拉三药联合。
  • 研究注册于ClinicalTrials.gov,编号NCT03113643。

主要发现

  • 3天Tagraxofusp给药的不良事件符合预期,未提示Tagraxofusp或阿扎胞苷±维奈克拉联合时毒性增加。
  • Tagraxofusp推荐2期剂量为12 μg/kg/天连用3天,联合7天阿扎胞苷±21天维奈克拉。
  • 在26例初治欧洲白血病网不良风险急性髓系白血病扩展队列(中位年龄71岁,50% TP53突变)中,三药联合诱导缓解率69%(n=18/26;完全缓解39%,伴计数不完全恢复的完全缓解19%,形态学无白血病状态12%)。
  • 13例TP53突变患者中,7/13(54%)达到完全缓解/伴计数不完全恢复的完全缓解/形态学无白血病状态(完全缓解=4,伴计数不完全恢复的完全缓解=2,形态学无白血病状态=1)。
  • 17例可检测缓解者中12例(71%)无流式可测量残留病;中位总生存14个月(95%CI,9.5-NA),中位无进展生存8.5个月(95%CI,5.1-NA)。

关键数值与推荐

  • Tagraxofusp推荐2期剂量为12 μg/kg/天连用3天,联合7天阿扎胞苷±21天维奈克拉。
  • 三药联合扩展队列诱导缓解率69%(n=18/26),其中完全缓解39%、伴计数不完全恢复的完全缓解19%、形态学无白血病状态12%。
  • TP53突变患者中54%(7/13)达到完全缓解/伴计数不完全恢复的完全缓解/形态学无白血病状态(完全缓解=4,伴计数不完全恢复的完全缓解=2,形态学无白血病状态=1)。
  • 可检测缓解者中71%(12/17)无流式可测量残留病。
  • 中位总生存14个月(95%CI,9.5-NA),中位无进展生存8.5个月(95%CI,5.1-NA)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD123, a subunit of the interleukin-3 receptor, is expressed on ∼80% of acute myeloid leukemias (AMLs). Tagraxofusp (TAG), recombinant interleukin-3 fused to a truncated diphtheria toxin payload, is a first-in-class drug targeting CD123 approved for treatment of blastic plasmacytoid dendritic cell neoplasm. We previously found that AMLs with acquired resistance to TAG were re-sensitized by the DNA hypomethylating agent azacitidine (AZA) and that TAG-exposed cells became more dependent on the antiapoptotic molecule BCL-2. Here, we report a phase 1b study in 56 adults with CD123-positive AML or high-risk myelodysplastic syndrome (MDS), first combining TAG with AZA in AML/MDS, and subsequently TAG, AZA, and the BCL-2 inhibitor venetoclax (VEN) in AML. Adverse events with 3-day TAG dosing were as expected, without indication of increased toxicity of TAG or AZA+/-VEN in combination. The recommended phase 2 dose of TAG was 12 μg/kg/day for 3 days, with 7-day AZA +/- 21-day VEN. In an expansion cohort of 26 patients (median age 71) with previously untreated European LeukemiaNet adverse-risk AML (50% TP53 mutated), triplet TAG-AZA-VEN induced response in 69% (n=18/26; 39% complete remission [CR], 19% complete remission with incomplete count recovery [CRi], 12% morphologic leukemia-free state [MLFS]). Among 13 patients with TP53 mutations, 7/13 (54%) achieved CR/CRi/MLFS (CR = 4, CRi = 2, MLFS = 1). Twelve of 17 (71%) tested responders had no flow measurable residual disease. Median overall survival and progression-free survival were 14 months (95% CI, 9.5-NA) and 8.5 months (95% CI, 5.1-NA), respectively. In summary, TAG-AZA-VEN shows encouraging safety and activity in high-risk AML, including TP53-mutated disease, supporting further clinical development of TAG combinations. The study was registered on ClinicalTrials.gov as #NCT03113643.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lane AA, Garcia JS, Raulston EG, et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024. PMID: 38052038. doi:10.1182/bloodadvances.2023011721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。